Gandotinib

Gandotinib (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 (Janus kinase) inhibitor, with additional minor inhibition of STAT3.

Gandotinib

Clinical data
Routes of administration	PO
ATC code	none
Identifiers
IUPAC name 3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine
CAS Number	1229236-86-5 Y
PubChem CID	46213929
ChemSpider	25027412
UNII	ANC71R916O
KEGG	D10365
CompTox Dashboard (EPA)	DTXSID20153789
Chemical and physical data
Formula	C23H25ClFN7O
Molar mass	469.95 g·mol−1
3D model (JSmol)	Interactive image
SMILES C12C(=CC(=NN1C(=C(N=2)C)CC1C(=CC(=CC=1)Cl)F)NC1=NNC(=C1)C)CN1CCOCC1
InChI InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30) Key:SQSZANZGUXWJEA-UHFFFAOYSA-N

In phase I trial, 16% of patients receiving the drug developed tumor lysis syndrome.^[1] A phase II trial is underway for patients with myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, or myelofibrosis, who had failed ruxolitinib.^[2][3]